HC Wainwright Predicts Alector’s Q1 Earnings (NASDAQ:ALEC)

Alector, Inc. (NASDAQ:ALEC) – Research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Alector in a report issued on Tuesday, November 26th. HC Wainwright analyst A. Fein expects that the company will post earnings of ($0.42) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $35.00 price target on the stock. The consensus estimate for Alector’s current full-year earnings is ($1.87) per share. HC Wainwright also issued estimates for Alector’s Q2 2025 earnings at ($0.42) EPS, Q3 2025 earnings at ($0.42) EPS, Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($1.66) EPS, FY2026 earnings at ($1.60) EPS, FY2027 earnings at ($0.76) EPS and FY2028 earnings at ($0.39) EPS.

Other research analysts also recently issued reports about the company. BTIG Research cut their price objective on Alector from $16.00 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday. Morgan Stanley lowered shares of Alector from an “equal weight” rating to an “underweight” rating and dropped their price target for the company from $10.00 to $3.00 in a research report on Tuesday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Alector in a report on Tuesday. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $14.00.

Alector Price Performance

Shares of NASDAQ:ALEC opened at $2.55 on Thursday. The stock has a market capitalization of $249.23 million, a P/E ratio of -1.50 and a beta of 0.66. The business has a 50-day moving average of $4.75 and a two-hundred day moving average of $5.02. Alector has a fifty-two week low of $2.37 and a fifty-two week high of $8.90.

Alector (NASDAQ:ALEC) last posted its earnings results on Wednesday, November 6th. The company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.10. Alector had a negative net margin of 257.54% and a negative return on equity of 108.77%. The company had revenue of $15.34 million during the quarter, compared to the consensus estimate of $16.33 million.

Insiders Place Their Bets

In other news, CEO Arnon Rosenthal sold 26,499 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $4.88, for a total transaction of $129,315.12. Following the completion of the transaction, the chief executive officer now owns 1,948,746 shares of the company’s stock, valued at approximately $9,509,880.48. This represents a 1.34 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Sara Kenkare-Mitra sold 13,926 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $4.88, for a total transaction of $67,958.88. Following the completion of the sale, the insider now owns 291,715 shares of the company’s stock, valued at approximately $1,423,569.20. The trade was a 4.56 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 47,722 shares of company stock valued at $232,883 in the last three months. Company insiders own 9.10% of the company’s stock.

Hedge Funds Weigh In On Alector

Hedge funds have recently made changes to their positions in the business. Gladius Capital Management LP bought a new stake in shares of Alector in the 2nd quarter valued at approximately $29,000. Point72 DIFC Ltd acquired a new position in Alector in the third quarter valued at about $29,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Alector during the third quarter worth about $40,000. nVerses Capital LLC acquired a new position in shares of Alector in the 3rd quarter worth approximately $51,000. Finally, Lazard Asset Management LLC acquired a new position in shares of Alector in the 1st quarter worth approximately $59,000. Institutional investors and hedge funds own 85.83% of the company’s stock.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.